Angelalign Technology Inc. (HKG:6699)
70.30
+0.15 (0.21%)
Jan 21, 2026, 3:14 PM HKT
Angelalign Technology Revenue
Angelalign Technology had revenue of $80.68M USD in the quarter ending June 30, 2025, with 33.05% growth. This brings the company's revenue in the last twelve months to $308.87M, up 25.52% year-over-year. In the year 2024, Angelalign Technology had annual revenue of $268.79M with 28.23% growth.
Revenue (ttm)
$308.87M
Revenue Growth
+25.52%
P/S Ratio
4.94
Revenue / Employee
$86.37K
Employees
3,576
Market Cap
11.98B HKD
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 268.79M | 59.17M | 28.23% |
| Dec 31, 2023 | 209.62M | 25.53M | 13.87% |
| Dec 31, 2022 | 184.09M | -16.09M | -8.04% |
| Dec 31, 2021 | 200.18M | 75.11M | 60.06% |
| Dec 31, 2020 | 125.07M | 32.31M | 34.83% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| JD Health International | 71.34B |
| BeOne Medicines AG | 38.69B |
| Alibaba Health Information Technology | 36.09B |
| Sino Biopharmaceutical | 33.49B |
| CSPC Pharmaceutical Group | 28.65B |
| WuXi Biologics | 21.98B |
| Hansoh Pharmaceutical Group Company | 14.45B |
| Innovent Biologics | 12.52B |